Copenhagen -based SnipperMicrobial CRISPR-Medicin, a biotech company, has announced the increase in CRISPR-based therapy for the infection of cytic fibrosis airway, which will increase the series B to advance the CRISPR-based therapy, with antibiotics resistance and blood cancer patients supporting SNPR 00 00
The new investors who participated in the round are the Cyric Fibrosis Foundation and the German Federal Agency for Breaking Innovation (Sprin-D) as well as the existing investor Londbecfonden Biocipital, Northeast Family Office and Wellington Partners.
“To prevent blood flow infection we move forward with SNIPR001’s clinical development as an important milestone for SNIPR Biome and extend our infectious disease pipeline to target critical importance of critical importance“Said GrandahChief Executive Officer and co-founder of Sniper Biome. “This support shows the importance of addressing the unique position of SNIPR biome in the landscape of infectious diseases and developmentThe “
Established in the 21st, the SNIPR Biome is a clinical-stage biotech company that invented the development of CRISPR-Medicine. They focus on a fancy use of CRISPR-Cass technology to better treat human disease through the correct killing of bacteria or gene change.
The technology causes electoral, precise and ultra-Rapid killing to eliminate target bacteria and remove antibiotics genes, while the rest of the patient’s microbial community left intact. Furthermore, SNIPR technology is used to create CRISPR-Medicin designed to transform and produce selected in the target regions of the gastrointestinal tract. The SNIPR Biome provides the Bacteria based on their specific genome, a programmable way to provide the CRISPR-based immune system of natural bacteria.
SNIPR Biome alleged that the first company was approved by CRISPR therapeutic to orally dose people and to use CRISPR to target microbiomes.
SNIPR001 is currently being evaluated in the study of a phase 1B (NCT 06938867) in eight cancer centers in the United States and is funded by Carb-X. SNIPR technology is used in collaboration with Carb-X, Gates Foundation, cystic fibrosis foundation, IPath, Sprin-D, and MD Anderson Cancer Center.
This fund will support the development of a CRISPR-CAS therapy aimed at the airway infection caused by pseudomonas aurouginosa among people with cystic fibrosis (CF). In addition, it will enable the progress of a CRISPR-based microbial intervention designed to eliminate antibiotics resistance genes through various bacteria species and the environment.
In patients with hematologic cancer patients, including ongoing phase 1B trials, the company’s CRISPR-based product, SNIPR 001 clinical development will further.
[publish_date
